Amsacrine (Synonyms: 安吖啶; m-AMSA; acridinyl anisidide)

目錄號: HY-13551 純度: 99.91%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南

摩爾計算器

Amsacrine (m-AMSA; acridinyl anisidide) 是腫瘤細(xì)胞 DNA 嵌入劑，還能抑制拓?fù)洚悩?gòu)酶 II。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)

Amsacrine Chemical Structure

CAS No. : 51264-14-3

1. 客戶無需承擔(dān)相應(yīng)的運輸費用。

2. 同一機構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機構(gòu)（單位）一年內(nèi)

可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價格	是否有貨
10 mM * 1 mL in DMSO	￥792	In-stock
5 mg	￥720	In-stock
10 mg	￥1125	In-stock
25 mg	￥2250	In-stock
50 mg	￥3600	In-stock
100 mg	￥5760	In-stock
200 mg		詢價
500 mg		詢價

or 大包裝詢價

* Please select Quantity before adding items.

Customer Review

Other Forms of Amsacrine:

MCE 顧客使用本產(chǎn)品發(fā)表的 5 篇科研文獻(xiàn)

•Cell Metab. 2022 Feb 7;34(3):424-440.e7. [Abstract]
•J Adv Res. 2023 Jun 6;S2090-1232(23)00148-0. [Abstract]
•J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
•Nucleic Acid Ther. 2023 Jun 30. [Abstract]
•bioRxiv. September 29, 2021.

Amsacrine 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

查看 Topoisomerase 亞型特異性產(chǎn)品:

查看所有亞型

Topoisomerase Topo I Topo II

生物活性
實驗參考方法
純度 & 產(chǎn)品資料
參考文獻(xiàn)

生物活性

Amsacrine (m-AMSA; acridinyl anisidide) is an inhibitor of topoisomerase II, and acts as an antineoplastic agent which can intercalates into the DNA of tumor cells.

IC₅₀ & Target^[1]

Topoisomerase II

細(xì)胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
2008	IC₅₀	4.31 μM Compound: m-AMSA	Cytotoxicity against human 2008 cells after 72 hrs by MTT assay Cytotoxicity against human 2008 cells after 72 hrs by MTT assay	[PMID: 19101158]
A2780	GI₅₀	0.027 μM Compound: m-AMSA	Growth inhibition of human A2780 cells incubated for 72 hrs by trypan blue assay Growth inhibition of human A2780 cells incubated for 72 hrs by trypan blue assay	[PMID: 32435372]
A2780	IC₅₀	0.1 μM Compound: m-AMSA	Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells. Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.	[PMID: 7658436]
A-431	IC₅₀	0.17 μM Compound: 1, m-AMSA	Growth inhibition in human A431 cells after 72 hrs by trypan blue assay Growth inhibition in human A431 cells after 72 hrs by trypan blue assay	[PMID: 21216603]
A-431	IC₅₀	5.89 μM Compound: m-AMSA	Cytotoxicity against human A431 cells after 72 hrs by MTT assay Cytotoxicity against human A431 cells after 72 hrs by MTT assay	[PMID: 19101158]
A549	IC₅₀	0.03 μM Compound: 1	Inhibitory activity against A549 cell line using MTT assay(Wild type p53) Inhibitory activity against A549 cell line using MTT assay(Wild type p53)	[PMID: 10780913]
A549	IC₅₀	22.2 μM Compound: m-Amsa	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33479643]
A549	IC₅₀	3.52 μM Compound: m-AMSA	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19101158]
A549	IC₅₀	5.96 μM Compound: 2; m-AMSA	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 27060757]
CCRF-CEM	IC₅₀	0.03 μM Compound: m-AMSA	Antiproliferative against human CCRF-CEM cells incubated for 72 hrs by MTT assay Antiproliferative against human CCRF-CEM cells incubated for 72 hrs by MTT assay	[PMID: 31635931]
CCRF-CEM	IC₅₀	0.18 μM Compound: 2; m-AMSA	Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay	[PMID: 27060757]
CCRF-CEM	IC₅₀	130 nM Compound: amsacrine	Cytotoxicity against human CCRF-CEM cells after 72 hrs Cytotoxicity against human CCRF-CEM cells after 72 hrs	[PMID: 18329887]
CHO-AA8	IC₅₀	0.6 nM Compound: Amsacrine	Inhibitory activity of compound for AA8 cells to reduce cell density by 50% (exposed to compound for 4 hours) Inhibitory activity of compound for AA8 cells to reduce cell density by 50% (exposed to compound for 4 hours)	[PMID: 2909741]
COLO 205	IC₅₀	1.1 μM Compound: Amsacrine	Antiproliferative activity against human COLO205 cells after 72 hrs by MTT assay Antiproliferative activity against human COLO205 cells after 72 hrs by MTT assay	[PMID: 22546208]
DLD-1	IC₅₀	0.08 μM Compound: amsacrine	Cytotoxicity against human DLD1 cells by Hoechst test Cytotoxicity against human DLD1 cells by Hoechst test	[PMID: 18656367]
DLD-1	IC₅₀	0.57 μM Compound: amsacrine	Cytotoxicity against human DLD1 cells by resazurin reduction test Cytotoxicity against human DLD1 cells by resazurin reduction test	[PMID: 18656367]
DU-145	IC₅₀	0.3 μM Compound: Amsacrine	Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay	[PMID: 22546208]
F460pv8/eto	IC₅₀	0.04 μM Compound: 1	Inhibitory activity against F460pv8/eto cell line using MTT assay Inhibitory activity against F460pv8/eto cell line using MTT assay	[PMID: 10780913]
Fibroblast	IC₅₀	2 μM Compound: amsacrine	Cytotoxicity against human fibroblast cells by Hoechst test Cytotoxicity against human fibroblast cells by Hoechst test	[PMID: 18656367]
Fibroblast	IC₅₀	4.2 μM Compound: amsacrine	Cytotoxicity against human fibroblast cells by resazurin reduction test Cytotoxicity against human fibroblast cells by resazurin reduction test	[PMID: 18656367]
HCC1937	IC₅₀	7.85 μM Compound: m-AMSA	Antiproliferative activity against human HCC1937 cells harboring BRCA1 mutant after 72 hrs by MTT assay Antiproliferative activity against human HCC1937 cells harboring BRCA1 mutant after 72 hrs by MTT assay	[PMID: 28763648]
HCT-116	IC₅₀	< 1 μM Compound: m-AMSA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29954683]
HCT-116	IC₅₀	0.7 μM Compound: m-AMSA	Cytotoxicity against human HCT116 cells by XTT assay Cytotoxicity against human HCT116 cells by XTT assay	[PMID: 17368022]
HCT-116	IC₅₀	0.93 μM Compound: 2; m-AMSA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 27060757]
HCT-116	IC₅₀	3.89 μM Compound: m-AMSA	Antiproliferative activity against human HCT116 cells expressing topoisomerase-1 after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells expressing topoisomerase-1 after 72 hrs by MTT assay	[PMID: 28763648]
HCT-15	IC₅₀	0.3 μM Compound: Amsacrine	Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay	[PMID: 22546208]
HCT-8	IC₅₀	0.3 μM Compound: Amsacrine	Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 22546208]
HEK293	IC₅₀	5 μM Compound: amsacrine	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy	[PMID: 18788725]
HeLa	IC₅₀	0.012 μM Compound: 1, m-AMSA	Growth inhibition in human HeLa cells after 72 hrs by trypan blue assay Growth inhibition in human HeLa cells after 72 hrs by trypan blue assay	[PMID: 21216603]
HeLa	IC₅₀	0.012 μM Compound: m-amsacrine	Antiproliferative activity against human HeLa cells after 72 hrs by trypan blue test Antiproliferative activity against human HeLa cells after 72 hrs by trypan blue test	[PMID: 18077173]
HeLa	GI₅₀	0.031 μM Compound: m-AMSA	Growth inhibition of human HeLa cells incubated for 72 hrs by trypan blue assay Growth inhibition of human HeLa cells incubated for 72 hrs by trypan blue assay	[PMID: 32435372]
HeLa	IC₅₀	0.34 μM Compound: 2; m-AMSA	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 27060757]
HeLa	EC₅₀	0.72 μM Compound: m-AMSA	Tested for inhibitory activity against Topoisomerase II isolated from HeLa cells by using SDS-K+ precipitation method Tested for inhibitory activity against Topoisomerase II isolated from HeLa cells by using SDS-K+ precipitation method	10.1016/S0960-894X(00)80048-7
HeLa	EC₅₀	0.72 μM Compound: mAMSA	Compound was tested for topoisomerase II inhibition in purified HeLa cells by SDS/K+ precipitation method Compound was tested for topoisomerase II inhibition in purified HeLa cells by SDS/K+ precipitation method	10.1016/0960-894X(95)00044-T
HeLa	EC₅₀	0.72 μM Compound: m-AMSA	Inhibitory activity in a cell-free assay of DNA cleavage mediated by purified HeLa cell topoisomerase II. Inhibitory activity in a cell-free assay of DNA cleavage mediated by purified HeLa cell topoisomerase II.	10.1016/0960-894X(95)00043-S
HeLa	EC₅₀	0.72 μM Compound: 5 (m-AMSA)	Tested for inhibition of topoisomerase II isolated from HeLa cells by DNA-cleavage assay Tested for inhibition of topoisomerase II isolated from HeLa cells by DNA-cleavage assay	[PMID: 8410993]
HeLa	IC₅₀	19.19 μM Compound: m-AMSA	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28511910]
HeLa	IC₅₀	9.5 μM Compound: m-AMSA	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19364657]
HeLa	IC₅₀	9.5 μM Compound: Amsacrine	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 18035542]
HepG2	IC₅₀	5.21 μM Compound: m-AMSA	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28511910]
HL-60	IC₅₀	0.0051 μM Compound: m-amsacrine	Antiproliferative activity against human HL60 cells after 72 hrs by trypan blue test Antiproliferative activity against human HL60 cells after 72 hrs by trypan blue test	[PMID: 18077173]
HL-60	IC₅₀	0.006 μM Compound: 1, m-AMSA	Growth inhibition in human HL60 cells after 72 hrs by trypan blue assay Growth inhibition in human HL60 cells after 72 hrs by trypan blue assay	[PMID: 21216603]
HL-60	IC₅₀	0.08 μM Compound: Amsacrine	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 22546208]
HL-60	IC₅₀	1.15 μM Compound: m-AMSA	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 19101158]
HT-1080	GI₅₀	1.6 μM Compound: m-Amsa	Cytocidal activity against human HT1080 cells assessed as growth inhibition after 48 hrs by SRB assay Cytocidal activity against human HT1080 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 22503207]
HT-1080	GI₅₀	1.6 μM Compound: m-Amsa	Antiproliferative activity against human HT1080 cells after 48 hrs by SRB assay Antiproliferative activity against human HT1080 cells after 48 hrs by SRB assay	[PMID: 18403058]
HT-29	GI₅₀	16.8 μM Compound: m-Amsa	Cytocidal activity against human HT-29 cells assessed as growth inhibition after 48 hrs by SRB assay Cytocidal activity against human HT-29 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 22503207]
HT-29	GI₅₀	16.8 μM Compound: m-Amsa	Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay	[PMID: 18403058]
HT-29	IC₅₀	559 nM Compound: m-AMSA	Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay	[PMID: 2778449]
Jurkat	IC₅₀	< 1 μM Compound: 3	Concentration required to reduce growth of human jurkat leukemia cells to 50% of control cultures, determined using a 72 hr continuous exposure Concentration required to reduce growth of human jurkat leukemia cells to 50% of control cultures, determined using a 72 hr continuous exposure	[PMID: 8182707]
Jurkat	IC₅₀	0.02 μM Compound: amsacrine	Cytotoxicity against human Jurkat cells by Hoechst test Cytotoxicity against human Jurkat cells by Hoechst test	[PMID: 18656367]
Jurkat	IC₅₀	0.08 μM Compound: amsacrine	Cytotoxicity against human Jurkat cells by resazurin reduction test Cytotoxicity against human Jurkat cells by resazurin reduction test	[PMID: 18656367]
K562	IC₅₀	0.023 μM Compound: amsacrine (m-AMSA)	Cytotoxicity against human K562 cells after 5 days by XTT assay Cytotoxicity against human K562 cells after 5 days by XTT assay	[PMID: 18076140]
K562	IC₅₀	0.71 μM Compound: m-AMSA	Antiproliferative against human K562 cells incubated for 72 hrs by MTT assay Antiproliferative against human K562 cells incubated for 72 hrs by MTT assay	[PMID: 31635931]
K562	IC₅₀	0.88 μM Compound: m-AMSA	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 28511910]
K562	IC₅₀	13.8 μM Compound: m-Amsa	Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33479643]
K562	IC₅₀	19.9 μM Compound: m-AMSA	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 19364657]
K562	IC₅₀	19.9 μM Compound: Amsacrine	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 18035542]
M21	GI₅₀	49.6 μM Compound: m-Amsa	Cytocidal activity against human M21 cells assessed as growth inhibition after 48 hrs by SRB assay Cytocidal activity against human M21 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 22503207]
M21	GI₅₀	49.6 μM Compound: m-Amsa	Antiproliferative activity against human M21 cells after 48 hrs by SRB assay Antiproliferative activity against human M21 cells after 48 hrs by SRB assay	[PMID: 18403058]
M4Beu cell line	IC₅₀	0.4 μM Compound: amsacrine	Cytotoxicity against human M4Beu cells by Hoechst test Cytotoxicity against human M4Beu cells by Hoechst test	[PMID: 18656367]
M4Beu cell line	IC₅₀	0.74 μM Compound: amsacrine	Cytotoxicity against human M4Beu cells by resazurin reduction test Cytotoxicity against human M4Beu cells by resazurin reduction test	[PMID: 18656367]
MCF7	IC₅₀	0.075 μM Compound: 1	Inhibitory activity against MCF-7 wt cell line using MTT assay (ER+,pgR+,wildtype p53) Inhibitory activity against MCF-7 wt cell line using MTT assay (ER+,pgR+,wildtype p53)	[PMID: 10780913]
MCF7	IC₅₀	0.075 μM Compound: 1	Inhibitory activity against MCF7wt cell line using MTT assay Inhibitory activity against MCF7wt cell line using MTT assay	[PMID: 10780913]
MCF7	IC₅₀	0.91 μM Compound: m-Amsa	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31421632]
MCF7	IC₅₀	21.7 μM Compound: m-AMSA	Cytotoxicity against human MCF7 cells by XTT assay Cytotoxicity against human MCF7 cells by XTT assay	[PMID: 18093835]
MCF7	IC₅₀	21.7 μM Compound: m-AMSA	Cytotoxicity against human MCF7 cells by XTT assay Cytotoxicity against human MCF7 cells by XTT assay	[PMID: 17368022]
MCF7	IC₅₀	26.76 μM Compound: 2; m-AMSA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 27060757]
MCF7	IC₅₀	5.13 μM Compound: m-AMSA	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19101158]
MCF7	GI₅₀	5.6 μM Compound: m-Amsa	Cytocidal activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay Cytocidal activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 22503207]
MCF7	GI₅₀	5.6 μM Compound: m-Amsa	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 18403058]
MCF7	IC₅₀	8.7 μM Compound: m-AMSA	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 28763648]
MDA-MB-231	IC₅₀	0.14 μM Compound: 1	Inhibitory activity against MDA-231 cell line using MTT assay (ER-,EGFR+,mutant p53) Inhibitory activity against MDA-231 cell line using MTT assay (ER-,EGFR+,mutant p53)	[PMID: 10780913]
MDA-MB-231	IC₅₀	10.05 μM Compound: m-AMSA	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 29954683]
MDA-MB-468	IC₅₀	0.49 μM Compound: 1	Inhibitory activity against MDA-468 cell line using MTT assay (ER-, amplified EGFR, mutant p53) Inhibitory activity against MDA-468 cell line using MTT assay (ER-, amplified EGFR, mutant p53)	[PMID: 10780913]
MDA-MB-468	IC₅₀	8.5 μM Compound: m-AMSA	Cytotoxicity against human MDA-MB468 cells by XTT assay Cytotoxicity against human MDA-MB468 cells by XTT assay	[PMID: 17368022]
MRC5	IC₅₀	15.4 μM Compound: m-Amsa	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33479643]
MSTO-211H	GI₅₀	0.019 μM Compound: m-AMSA	Growth inhibition of human MSTO-211H cells incubated for 72 hrs by trypan blue assay Growth inhibition of human MSTO-211H cells incubated for 72 hrs by trypan blue assay	[PMID: 32435372]
NCI/ADR-RES	IC₅₀	1.165 μM Compound: 1	Inhibitory activity against MCF-7/adr cell line using MTT assay Inhibitory activity against MCF-7/adr cell line using MTT assay	[PMID: 10780913]
NCI-H226	IC₅₀	1.01 μM Compound: 1	Inhibitory activity against NCI-H226 cell line using MTT assay(mutant p53) Inhibitory activity against NCI-H226 cell line using MTT assay(mutant p53)	[PMID: 10780913]
NCI-H322M	IC₅₀	0.21 μM Compound: 1	Inhibitory activity against NCI-H322 cell line using MTT assay(mutant p53) Inhibitory activity against NCI-H322 cell line using MTT assay(mutant p53)	[PMID: 10780913]
NCI-H358	IC₅₀	0.15 μM Compound: 1	Inhibitory activity against NCI-H358 cell line using MTT assay(mutant p53) Inhibitory activity against NCI-H358 cell line using MTT assay(mutant p53)	[PMID: 10780913]
NCI-H460	IC₅₀	0.06 μM Compound: 1	Inhibitory activity against NCI-H460 cell line using MTT assay Inhibitory activity against NCI-H460 cell line using MTT assay	[PMID: 10780913]
NCI-H460	IC₅₀	0.06 μM Compound: 1	Inhibitory activity against NCI-H460 cell line using MTT assay(Wild type p53) Inhibitory activity against NCI-H460 cell line using MTT assay(Wild type p53)	[PMID: 10780913]
NCI-H460	IC₅₀	0.2 μM Compound: 1	Inhibitory activity against H460pv8 cell line using MTT assay Inhibitory activity against H460pv8 cell line using MTT assay	[PMID: 10780913]
NCI-H647	IC₅₀	0.07 μM Compound: 1	Inhibitory activity against NCI-H647 cell line using MTT assay(mutant p53) Inhibitory activity against NCI-H647 cell line using MTT assay(mutant p53)	[PMID: 10780913]
OVCAR-8	IC₅₀	1.4 μM Compound: Amsacrine	Antiproliferative activity against human OVCAR8 cells after 72 hrs by MTT assay Antiproliferative activity against human OVCAR8 cells after 72 hrs by MTT assay	[PMID: 22546208]
P388	IC₅₀	0.15 μM Compound: mAMSA	In Vitro Cytotoxicity was measured by quantifying clonogenic survival in soft agar following a 1 hr transient exposure of P388 mouse leukemia cells to compound In Vitro Cytotoxicity was measured by quantifying clonogenic survival in soft agar following a 1 hr transient exposure of P388 mouse leukemia cells to compound	10.1016/0960-894X(96)00230-2
P388	IC₅₀	0.15 μM Compound: mAMSA	In vitro cytotoxicity measured by quantifying clonogenic survival in soft agar following a 1-hour transient exposure of p388 mouse leukemia cells. In vitro cytotoxicity measured by quantifying clonogenic survival in soft agar following a 1-hour transient exposure of p388 mouse leukemia cells.	[PMID: 9733489]
P388	IC₅₀	229 nM Compound: m-AMSA	Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay	[PMID: 2778449]
PBMC	IC₅₀	21.7 μM Compound: Amsacrine	Cytotoxicity against human PBMC after 72 hrs by alamar blue assay Cytotoxicity against human PBMC after 72 hrs by alamar blue assay	[PMID: 22546208]
PC-3	IC₅₀	3.3 μM Compound: Amsacrine	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 22546208]
RAW264.7	CC₅₀	95.5 μM Compound: m-Amsa	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31421632]
SF-295	IC₅₀	0.5 μM Compound: Amsacrine	Antiproliferative activity against human SF295 cells after 72 hrs by MTT assay Antiproliferative activity against human SF295 cells after 72 hrs by MTT assay	[PMID: 22546208]
SK-BR-3	IC₅₀	0.06 μM Compound: 1	Inhibitory activity against SKBR-3 cell line using MTT assay (ER-amplified erB2,mutant p53) Inhibitory activity against SKBR-3 cell line using MTT assay (ER-amplified erB2,mutant p53)	[PMID: 10780913]
SW480	IC₅₀	27.7 μM Compound: m-AMSA	Cytotoxicity against human SW480 cells after 72 hrs by MTT assay Cytotoxicity against human SW480 cells after 72 hrs by MTT assay	[PMID: 19364657]
SW480	IC₅₀	27.7 μM Compound: Amsacrine	Antiproliferative activity against human SW480 cells after 72 hrs by MTT assay Antiproliferative activity against human SW480 cells after 72 hrs by MTT assay	[PMID: 18035542]
SW-620	IC₅₀	0.3 μM Compound: Amsacrine	Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay	[PMID: 22546208]
SW-620	IC₅₀	16.7 μM Compound: m-AMSA	Cytotoxicity against human SW620 cells after 72 hrs by MTT assay Cytotoxicity against human SW620 cells after 72 hrs by MTT assay	[PMID: 19364657]
SW-620	IC₅₀	16.7 μM Compound: Amsacrine	Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay	[PMID: 18035542]
T47D	IC₅₀	0.22 μM Compound: 1	Inhibitory activity against T47D cell line using MTT assay (ER+,mutant p53) Inhibitory activity against T47D cell line using MTT assay (ER+,mutant p53)	[PMID: 10780913]
T47D	IC₅₀	0.94 μM Compound: m-Amsa	Cytotoxicity against human T47D cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31421632]
U-937	IC₅₀	0.08 μM Compound: m-AMSA	Antiproliferative against human U937 cells incubated for 72 hrs by MTT assay Antiproliferative against human U937 cells incubated for 72 hrs by MTT assay	[PMID: 31635931]
U-937	IC₅₀	0.61 μM Compound: m-AMSA	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 29954683]
U-937	IC₅₀	0.61 μM Compound: m-AMSA	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 28511910]
V79	IC₅₀	5.8 μM Compound: Amsacrine	Cytotoxicity against chinese hamster V79 cells after 72 hrs by MTT assay Cytotoxicity against chinese hamster V79 cells after 72 hrs by MTT assay	[PMID: 22546208]
ZR-75-1	IC₅₀	0.18 μM Compound: 1	Inhibitory activity against ZR-75-1 cell line using MTT assay (ER+,pgr+,mutant p53) Inhibitory activity against ZR-75-1 cell line using MTT assay (ER+,pgr+,mutant p53)	[PMID: 10780913]

體外研究
(In Vitro)

Amsacrine (m-AMSA) 以濃度依賴性方式阻斷 HEK 293 細(xì)胞和爪蟾卵母細(xì)胞中的 HERG 電流，IC₅₀ 值分別為 209.4 nm 和 2.0 μM。Amsacrine 會導(dǎo)致激活 (-7.6 mV) 和失活 (-7.6 mV) 的電壓依賴性發(fā)生負(fù)偏移。Amsacrine對 HERG 電流的阻斷與頻率無關(guān)^[1]。使用不同濃度的 Amsacrine 對正常人淋巴細(xì)胞進(jìn)行的體外研究表明，染色體畸變水平增加，范圍從 8% 到 100%，并且 SCEs 增加，在研究的最低濃度下是正常水平的 1.5 倍 (0.005 μg/mL) 至正常值 (0.25 μg/mL) 的 12 倍^[3]。Amsacrine 誘導(dǎo)的 U937 細(xì)胞凋亡的特征在于 caspase-9 和 caspase-3 激活、細(xì)胞內(nèi) Ca²⁺ 濃度增加、線粒體去極化和 MCL1 下調(diào)。Amsacrine 通過降低其穩(wěn)定性來誘導(dǎo) MCL1 下調(diào)。此外，Amsacrine 處理的 U937 細(xì)胞顯示出 AKT 降解和 Ca²⁺ 介導(dǎo)的 ERK 失活^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

在用不同劑量的 Amsacrine (0.5-12 mg/kg) 處理的動物中，微核多染紅細(xì)胞的頻率在用 9 和 12 mg/kg 處理后顯著增加。此外，本研究首次證明 Amsacrine (m-AMSA) 在體內(nèi)有絲分裂期具有高致染色體斷裂發(fā)生率和低致染色體斷裂發(fā)生率，而諾考達(dá)唑在有絲分裂期具有高致染色體斷裂發(fā)生率和低致染色體斷裂發(fā)生率^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

393.46

Formula

C₂₁H₁₉N₃O₃S

CAS 號

51264-14-3

性狀

固體

顏色

Orange to red

中文名稱

安吖啶；胺苯吖啶

運輸條件

Room temperature in continental US; may vary elsewhere.

儲存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性數(shù)據(jù)

細(xì)胞實驗：

DMSO 中的溶解度 : 9.3 mg/mL (23.64 mM; 超聲加熱助溶; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

配制儲備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	2.5416 mL	12.7078 mL	25.4155 mL
5 mM	0.5083 mL	2.5416 mL	5.0831 mL
10 mM	0.2542 mL	1.2708 mL	2.5416 mL

查看完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時，請在2年內(nèi)使用， -20°C儲存時，請在1年內(nèi)使用。

摩爾計算器
稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動物實驗：

請根據(jù)您的實驗動物和給藥方式選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

方案一

請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.35 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。

動物溶解方案計算器

請輸入動物實驗的基本信息：

給藥劑量

mg/kg

動物的平均體重

每只動物的給藥體積

μL

動物數(shù)量

只

由于實驗過程有損耗，建議您多配一只動物的量

請輸入您的動物體內(nèi)配方組成：

DMSO +

Tween-80 +

Saline

如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。

方案所需 助溶劑 包括：DMSO，，均可在 MCE 網(wǎng)站選購。，Tween 80，均可在 MCE 網(wǎng)站選購。

計算結(jié)果

工作液所需濃度 : mg/mL

儲備液配制方法 : mg 藥物溶于 μL DMSO（母液濃度為 mg/mL）。

您所需的儲備液濃度超過該產(chǎn)品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。

動物實驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。

連續(xù)給藥周期超過半月以上，請謹(jǐn)慎選擇該方案。

請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱（超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。

純度 & 產(chǎn)品資料

純度: 99.95%

選擇批次：

Data Sheet (652 KB) SDS (419 KB)

COA (294 KB) LCMS (267 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻(xiàn)

[1]. Thomas D, et al. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action. Br J Pharmacol. 2004 Jun;142(3):485-94. [Content Brief]

[2]. Attia SM. Molecular cytogenetic evaluation of the mechanism of genotoxic potential of amsacrine and nocodazole in mouse bone marrow cells. J Appl Toxicol. 2013 Jun;33(6):426-33. [Content Brief]

[3]. Kao-Shan CS, et al. Cytogenetic effects of amsacrine on human lymphocytes in vivo and in vitro. Cancer Treat Rep. 1984 Jul-Aug;68(7-8):989-97. [Content Brief]

[4]. Lee YC, et al. Amsacrine-induced apoptosis of human leukemia U937 cells is mediated by the inhibition of AKT- and ERK-induced stabilization of MCL1. Apoptosis. 2016 Oct 19 [Content Brief]

Animal Administration ^[2]	Amsacrine (m-AMSA) is investigated in three separated experiments. In the first experiment, animals are treated by intraperitoneal injection with 0.5, 1.5 and 4.5 mg/kg of amsacrine and bone marrow is sampled 24 h after treatment. Preliminary negative MN results at this sampling time lead to the use of 30 h sampling time for amsacrine. Thus, in the second experiment, mice are treated with 0.5, 1.5 and 4.5 mg/kg of Amsacrine (m-AMSA) and bone marrow is sampled 30 h after treatment. The doses and sampling times for amsacrine are chosen by reference to earlier studies and the selected doses are within the dose range used for human chemotherapy. The results again show that the micronuclei frequency in the bone marrow of mice is not affected by treatment with any of the selected doses of the test agent, at 30 h sampling time, thus, in the third experiment, mice are treated with 6, 9 and 12 mg/kg of amsacrine and bone marrow is sampled 24 and 30 h after treatment. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
參考文獻(xiàn)	[1]. Thomas D, et al. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action. Br J Pharmacol. 2004 Jun;142(3):485-94. [Content Brief] [2]. Attia SM. Molecular cytogenetic evaluation of the mechanism of genotoxic potential of amsacrine and nocodazole in mouse bone marrow cells. J Appl Toxicol. 2013 Jun;33(6):426-33. [Content Brief] [3]. Kao-Shan CS, et al. Cytogenetic effects of amsacrine on human lymphocytes in vivo and in vitro. Cancer Treat Rep. 1984 Jul-Aug;68(7-8):989-97. [Content Brief] [4]. Lee YC, et al. Amsacrine-induced apoptosis of human leukemia U937 cells is mediated by the inhibition of AKT- and ERK-induced stabilization of MCL1. Apoptosis. 2016 Oct 19 [Content Brief]

Animal Administration
^[2]

Amsacrine (m-AMSA) is investigated in three separated experiments. In the first experiment, animals are treated by intraperitoneal injection with 0.5, 1.5 and 4.5 mg/kg of amsacrine and bone marrow is sampled 24 h after treatment. Preliminary negative MN results at this sampling time lead to the use of 30 h sampling time for amsacrine. Thus, in the second experiment, mice are treated with 0.5, 1.5 and 4.5 mg/kg of Amsacrine (m-AMSA) and bone marrow is sampled 30 h after treatment. The doses and sampling times for amsacrine are chosen by reference to earlier studies and the selected doses are within the dose range used for human chemotherapy. The results again show that the micronuclei frequency in the bone marrow of mice is not affected by treatment with any of the selected doses of the test agent, at 30 h sampling time, thus, in the third experiment, mice are treated with 6, 9 and 12 mg/kg of amsacrine and bone marrow is sampled 24 and 30 h after treatment.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

參考文獻(xiàn)

[1]. Thomas D, et al. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action. Br J Pharmacol. 2004 Jun;142(3):485-94. [Content Brief]

[2]. Attia SM. Molecular cytogenetic evaluation of the mechanism of genotoxic potential of amsacrine and nocodazole in mouse bone marrow cells. J Appl Toxicol. 2013 Jun;33(6):426-33. [Content Brief]

[3]. Kao-Shan CS, et al. Cytogenetic effects of amsacrine on human lymphocytes in vivo and in vitro. Cancer Treat Rep. 1984 Jul-Aug;68(7-8):989-97. [Content Brief]

[4]. Lee YC, et al. Amsacrine-induced apoptosis of human leukemia U937 cells is mediated by the inhibition of AKT- and ERK-induced stabilization of MCL1. Apoptosis. 2016 Oct 19 [Content Brief]

Amsacrine 相關(guān)分類

完整儲備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.5416 mL	12.7078 mL	25.4155 mL	63.5389 mL
	5 mM	0.5083 mL	2.5416 mL	5.0831 mL	12.7078 mL
	10 mM	0.2542 mL	1.2708 mL	2.5416 mL	6.3539 mL
	15 mM	0.1694 mL	0.8472 mL	1.6944 mL	4.2359 mL
	20 mM	0.1271 mL	0.6354 mL	1.2708 mL	3.1769 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Amsacrine51264-14-3m-AMSA acridinyl anisidide安吖啶胺苯吖啶TopoisomeraseAutophagyInhibitorinhibitorinhibit

產(chǎn)品名稱：			* 需求量：
* 客戶姓名：			* Email：
* 電話：			* 公司或機構(gòu)名稱：
留言給我們：

產(chǎn)品名稱：			* Lot #：
* 客戶姓名：			* Email：
電話：			* 部門：
* 公司或機構(gòu)名稱：
留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個人或者非科研性質(zhì)的、非用于藥證申報使用等其他用途提供服務(wù)。	站點地圖隱私聲明
滬ICP備15051369號-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2024 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Amsacrine (Synonyms: 安吖啶; m-AMSA; acridinyl anisidide)

Customer Review

Other Forms of Amsacrine:

MCE 顧客使用本產(chǎn)品發(fā)表的 5 篇科研文獻(xiàn)

Amsacrine 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

查看 Topoisomerase 亞型特異性產(chǎn)品:

生物活性

實驗參考方法

純度 & 產(chǎn)品資料

參考文獻(xiàn)

摩爾計算器

稀釋計算器

Amsacrine 相關(guān)分類

完整儲備液配制表

Keywords:

您最近查看的產(chǎn)品:

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Amsacrine (Synonyms: 安吖啶; m-AMSA; acridinyl anisidide)

Customer Review

Other Forms of Amsacrine:

Amsacrine 相關(guān)抗體

MCE 顧客使用本產(chǎn)品發(fā)表的 5 篇科研文獻(xiàn)

Amsacrine 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

查看 Topoisomerase 亞型特異性產(chǎn)品:

生物活性

實驗參考方法

純度 & 產(chǎn)品資料

參考文獻(xiàn)

Amsacrine 相關(guān)抗體:

摩爾計算器

稀釋計算器

Amsacrine 相關(guān)分類

完整儲備液配制表

Keywords:

您最近查看的產(chǎn)品:

Request for HNMR Report

Request for HNMR Report

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z